stockportfolio.pro
Beta Bionics, Inc. (BBNX)
Healthcare · Medical Devices · NasdaqGM
Beta Bionics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $179,000 | $11.99M | $65.12M | $100.25M |
| Gross profit | $179,000 | $6.31M | $35.89M | $55.54M |
| Net income | $-64.75M | $-44.10M | $-54.76M | $-73.20M |
| Net margin | -36173.7% | -367.6% | -84.1% | -73.0% |
Source: Beta Bionics, Inc. SEC filings (10-K).
Explore 4 years of Beta Bionics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BBNX in your portfolio →
Beta Bionics, Inc. financial history by metric
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Beta Bionics, Inc. — frequently asked questions
What is Beta Bionics, Inc.'s revenue?
Beta Bionics, Inc. (BBNX) reported revenue of $100.25M for fiscal year 2025, up 53.9% from the prior year, according to its SEC filings.
Is Beta Bionics, Inc. profitable?
No — BBNX reported a net loss of $-73.20M in fiscal 2025.
What is BBNX's P/E ratio?
Beta Bionics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Beta Bionics, Inc. growing?
BBNX's revenue grew at roughly 724.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Beta Bionics, Inc. have?
As of fiscal year 2025, BBNX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Beta Bionics, Inc.'s gross margin?
BBNX's gross margin was 55.4% in fiscal 2025 — gross profit of $55.54M on revenue of $100.25M.
What is Beta Bionics, Inc.'s market cap?
Beta Bionics, Inc. (BBNX) has a market capitalization of about $615.62M, based on the latest data in our nightly-refreshed cache.
When does Beta Bionics, Inc.'s fiscal year end?
BBNX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Beta Bionics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.